Tumor reduction after SARS‑CoV‑2 infection in a patient with lung cancer: A case report

Zhang,Xiaoming; Chen,Jingyu; Sun,Jie; Gao,Shuyue; Zhao,Feiyu; Qian,Niansong

doi:10.3892/ol.2024.14302

Tumor reduction after SARS‑CoV‑2 infection in a patient with lung cancer: A case report

Authors:
- Xiaoming Zhang
- Jingyu Chen
- Jie Sun
- Shuyue Gao
- Feiyu Zhao
- Niansong Qian
View Affiliations

Affiliations: Department of Oncology, Hainan Hospital of Chinese PLA General Hospital, Sanya, Hainan 572000, P.R. China, Department of College English, School of Languages and Communication Studies, Beijing Jiaotong University, Beijing 100044, P.R. China, Department of Oncology, Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing 100039, P.R. China, Department of Oncology, Graduate School of Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China, Department of Respiratory and Critical Care Medicine, Eighth Medical Center of Chinese People's Liberation Army General Hospital, Beijing 100091, P.R. China
Published online on: February 22, 2024 https://doi.org/10.3892/ol.2024.14302
Article Number: 169
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the most common malignancies worldwide. Since the global outbreak of the coronavirus disease 2019 (COVID‑19) pandemic in 2020, the impact of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) on lung cancer has been extensively studied. Despite reports about SARS‑CoV‑2 infection inducing a significant increase in the number of medical visits for patients with cancer, the virus has also been reported to produce some unknown benefits. The present study reports the case of a patient with lung cancer whose tumor lesion was reduced in size after SARS‑CoV‑2 infection even though the therapeutic regimen remained unchanged. Although the mechanism involved is not yet understood, this case supports the novel idea of applying SARS‑CoV‑2 in oncolytic virotherapy.

View Figures

View References

1	Siegel RL, Miller KD, Wagle NS and Jemal A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023. View Article : Google Scholar : PubMed/NCBI
2	Petty WJ and Paz-Ares L: Emerging strategies for the treatment of small cell lung cancer: A review. JAMA Oncol. 9:419–429. 2023. View Article : Google Scholar : PubMed/NCBI
3	Vokes NI, Pan K and Le X: Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. Ther Adv Med Oncol. 15:175883592311614092023. View Article : Google Scholar : PubMed/NCBI
4	Zong Z, Wei Y, Ren J, Zhang L and Zhou F: The intersection of COVID-19 and cancer: Signaling pathways and treatment implications. Mol Cancer. 20:76–82. 2021. View Article : Google Scholar : PubMed/NCBI
5	Tsamakis K, Gavriatopoulou M, Schizas D, Stravodimou A, Mougkou A, Tsiptsios D, Sioulas V, Spartalis E, Sioulas AD, Tsamakis C, et al: Oncology during the COVID-19 pandemic: Challenges, dilemmas and the psychosocial impact on cancer patients. Oncol Lett. 20:441–447. 2020. View Article : Google Scholar : PubMed/NCBI
6	Bounassar-Filho JP, Boeckler-Troncoso L, Cajigas-Gonzalez J and Zavala-Cerna MG: SARS-CoV-2 as an oncolytic virus following reactivation of the immune system: A review. Int J Mol Sci. 24:243–249. 2023. View Article : Google Scholar : PubMed/NCBI
7	Meo C, Palma G, Bruzzese F, Budillon A, Napoli C and de Nigris F: Spontaneous cancer remission after COVID-19: Insights from the pandemic and their relevance for cancer treatment. J Transl Med. 21:273–278. 2023. View Article : Google Scholar : PubMed/NCBI
8	Rahimmanesh I, Shariati L, Dana N, Esmaeili Y, Vaseghi G and Haghjooy Javanmard S: Cancer occurrence as the upcoming complications of COVID-19. Front Mol Biosci. 8:8131752021. View Article : Google Scholar : PubMed/NCBI
9	Kurlapski M, Romanowicz G, Taszner M and Zaucha JM: SARS-CoV-2-induced remission of advanced classical Hodgkin lymphoma. Pol Arch Intern Med. 13:132–139. 2022.
10	Sollini M, Gelardi F, Carlo-Stella C and Chiti A: Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the ‘flare phenomenon’ to the ‘abscopal effect’. Eur J Nucl Med Mol Imaging. 48:2652–2654. 2021. View Article : Google Scholar : PubMed/NCBI
11	Barkhordar M, Rostami FT, Yaghmaie M, Abbaszadeh M, Chahardouli B and Mousavi SA: Spontaneous complete remission of acute myeloid leukemia in the absence of disease-modifying therapy following severe pulmonary involvement by coronavirus infectious disease-19. Case Rep Hematol. 2022:26036072022.PubMed/NCBI
12	Bulbul H, Nazli HE, Olgun A, Togay A and Kahraman DS: Spontaneous remission of chronic lymphocytic leukemia in a patient with SARS-CoV2. Leuk Res Rep. 18:103–106. 2022.PubMed/NCBI
13	Ottaiano A, Scala S, D'Alterio C, Trotta A, Bello A, Rea G, Picone C, Santorsola M, Petrillo A and Nasti G: Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection. Ther Adv Med Oncol. 13:175883592110114552021. View Article : Google Scholar : PubMed/NCBI
14	Ottaiano A, Santorsola M, Circelli L, Cascella M, Petrillo N, Perri F, Casillo M, Granata V, Ianniello M, Izzo F, et al: Genetic landscape of colorectal cancer patients manifesting tumor shrinkage during SARS-Cov-2 infection. Ther Adv Med Oncol. 14:175883592211383882022. View Article : Google Scholar : PubMed/NCBI
15	Buchler T, Fiser L, Benesova J, Jirickova H and Votrubova J: Spontaneous regression of metastatic renal cell carcinoma after SARS-CoV-2 infection: A report of two cases. Curr Oncol. 28:3403–3407. 2021. View Article : Google Scholar : PubMed/NCBI
16	Daly JL, Simonetti B, Klein K, Chen KE, Williamson MK, Anton-Plagaro C, Shoemark DK, Simon-Gracia L, Bauer M, Hollandi R, et al: Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 370:861–865. 2020. View Article : Google Scholar : PubMed/NCBI
17	Challenor S and Tucker D: SARS-CoV-2-induced remission of Hodgkin lymphoma. Br J Haematol. 192:415–421. 2021. View Article : Google Scholar : PubMed/NCBI
18	Pasin F, Mascalchi Calveri M, Calabrese A, Pizzarelli G, Bongiovanni I, Andreoli M, Cattaneo C and Rignanese G: Oncolytic effect of SARS-CoV2 in a patient with NK lymphoma. Acta Biomed. 91:Aug 10–2020.(Epub ahead of print).
19	Lin D, Shen Y and Liang T: Oncolytic virotherapy: Basic principles, recent advances and future directions. Signal Transduct Target Ther. 8:156–173. 2023. View Article : Google Scholar : PubMed/NCBI
20	Dock G: The influence of complicating diseases upon leukemia. Am J Med Sci. 127:563–592. 1904. View Article : Google Scholar
21	Kristin DP and Greg MD: Integrating innate and adaptive immunity in oncolytic virus therapy. Trends Cancer. 23:190–196. 2023.
22	Yun CO, Hong J and Yoon AR: Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. Front Immunol. 13:95–104. 2022. View Article : Google Scholar
23	Muscolini M, Tassone E and Hiscott J: Oncolytic immunotherapy: Can't start a fire without a spark. Cytokine Growth Factor Rev. 56:94–101. 2020. View Article : Google Scholar : PubMed/NCBI
24	Hamad A, Yusubalieva GM, Baklaushev VP, Chumakov PM and Lipatova AV: Recent developments in glioblastoma therapy: Oncolytic viruses and emerging future strategies. Viruses. 15:106–119. 2023. View Article : Google Scholar